Parabilis Medicines

Company snapshot

Expertise in Human and Animal health solid form characterization and formulation development. We deliver both experimental support and consulting services to biotechnology and pharmaceutical companies, not-for-profit organizations and complementary CROs. We are member of the association AFSSI, 1st French research center in Life Sciences, as a founding member and member of the board of Directors. S

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Parabilis Medicines. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Parabilis Medicines.

1. May 23, 2026 Clinical update

   FOG-001 — Phase 2

2. Aug 26, 2025 Patent grant

   Collections of peptides, peptide agents, and methods of use thereof

View all clinical trial activity →

• What is Parabilis Medicines?

  Drugabilis is a pharma organization headquartered in Villejust, FR. It trades on NYSE under ticker PBLS. Primary therapeutic focus areas include Cancer. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 1 patent record(s) to this entity from public FDA, EMA, Clin

• Is Parabilis Medicines publicly traded?

  Yes. Parabilis Medicines is listed with ticker PBLS on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Parabilis Medicines develop or market?

  No drug profiles are currently linked to Parabilis Medicines. Pipeline programs may still list investigational assets.

• What are the latest developments for Parabilis Medicines?

  In the last 12 months our linked public records show 1 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Parabilis Medicines focus on?

  Parabilis Medicines focuses on Cancer based on our analysis of their pipeline programs and drug development activities.